

30<sup>th</sup> May 2025

## Apollo Hospitals announces Q4FY25 & FY25 results

**FY25 Consolidated Revenue crosses Rs. 20,000 Crores milestone**  
**FY25 Healthcare Services Revenue crosses Rs. 10,000 Crores milestone**

**Q4 FY25 Consolidated Revenues grew 13% YoY to Rs. 5,592 Crores**  
**FY25 Consolidated Revenues rose 14% YoY to Rs. 21,794 Crores**

**Q4 FY25 Consolidated EBITDA increased 20% YoY to Rs. 770 Crores**  
**FY25 Consolidated EBITDA increased 26% YoY to Rs. 3,022 Crores**

**Q4 FY25 Consolidated PAT at Rs. 390 Crores, 54% YoY Growth**  
**FY25 Consolidated PAT at Rs. 1,446 Crores, 61% YoY Growth**

***Final Dividend of Rs. 10 per share, making for a Total Dividend of Rs. 19 per share, on face value of Rs. 5 per share.***

Announces significant expansion in the Sarjapur micro-market through the addition of 700 beds in 2 stages, to establish a dominant presence in the south-eastern part of Bengaluru with wide addressable market.

Stage 1: Acquisition of an existing 200 bedded hospital (leased facility).

Stage 2: Establishing a 500-bed greenfield hospital in close proximity

With the ongoing brownfield expansions in the city, the total bed strength in Bengaluru will be ~ 1,500 beds.

Brownfield expansion in Hyderabad by 160 beds through brownfield expansion at the existing Jubilee Hills and Secunderabad facilities.

Along with the upcoming facility in Gachibowli, Apollo Hospitals bed strength in Hyderabad will be ~1,400 beds.

With these announcements, Apollo Hospitals commits to adding over 4,300 beds over a period of 3 to 4 years, beginning FY26 with a total capital outlay of over Rs. 7,600 crores, with a balance capital outlay of over Rs. 5,500 crs.

***Apollo Hospitals crossed the landmark milestone of 25,000 transplants across its network, reaffirming its leadership in complex, high-acuity care.***

Dr. Prathap C Reddy, Chairman, Apollo Hospitals Enterprise Ltd. said: *"At Apollo, our mission has always gone beyond treating illness—it is about enabling every individual to live a healthier, happier life. FY25 was a defining year. With revenues crossing ₹20,000 crores and Healthcare Services surpassing ₹11,000 crores, we are humbled by the trust placed in us across India and beyond.*

*Technology expanded the possibilities of healing, but compassion remained our foundation. A strong rise in patient volumes is a testament to the deep confidence people have in Apollo's care and our differentiated Centers of Excellence. As we grow, our focus remains unwavering—making advanced, high-quality care accessible and affordable to all.*

*To address the rising burden of non-communicable diseases, we are intensifying our preventive care mission. Through Apollo ProHealth, we are set to globally launch pioneering wellness programs that redefine the healthcare landscape — shifting the focus from reactive treatment to proactive, preventive care.*

*Innovation remains our most powerful ally — from AI-powered diagnostics to precision robotic surgeries, all enabled by a digital backbone that is reimagining the entire patient- care journey, enabling care that is predictive, personalised, and scalable.*

*We are committed to growth and to the enhancement of our care touchpoints, with new hospitals to be commissioned this year in Pune, Kolkata, Hyderabad, Bangalore and Delhi NCR — and several more in varying stages of development. These state-of-the-art facilities will be equipped with cutting-edge medical technology, reinforcing our commitment to delivering world-class care at scale. Our over ₹7,600 crore investment over the next five years will add over 4,300 beds, with the first phase of ~ 2,000 beds already in progress—bringing advanced care closer to communities across India.*

*We are heartened by the performance of Apollo HealthCo and AHLL, two strong pillars of the integrated care network we have created for the consumer. Apollo Pharmacies crossed 6,600 stores this year and Apollo 24/7 commenced distribution of Insurance products to increase access to care. AHLL has strengthened its capability through its Global Reference Labs and highly specialized test menu updated for the latest medical advancements.*

*But what truly drives Apollo forward is our people—the doctors, nurses, and caregivers who carry our legacy in every life they touch. Their commitment is creating a healthcare system that is not only clinically world-class but also deeply human.*

*As we step into FY26, our purpose remains clear: to touch a billion lives, lead with innovation and empathy, and help build a healthier, stronger India for future generations."*

## Q4FY25 CONSOLIDATED RESULTS

### REVENUE

Q4FY25 Revenues grew 13% YoY to Rs. 5,592 Crores;

- Healthcare Services (HCS) Revenue at Rs. 2,822 Crores; 10% YoY growth
- AHLL Revenues at Rs. 394 Crores; 11% YoY growth
- Apollo HealthCo Revenues at Rs. 2,376 Crores; 17% YoY growth
- GMV of Apollo 24/7 at Rs. 795 Crores

### EBITDA

Q4FY25 Consolidated EBITDA grew 20% YoY to Rs. 770 Crores;

- Healthcare Services (HCS) EBITDA at Rs. 686 Crores; 16% YoY growth
- AHLL EBITDA at Rs. 47 Crores; 32% YoY growth
- Apollo HealthCo EBITDA at Rs. 36 Crores

### PAT

Q4FY25 Consolidated PAT grew 54% YoY to Rs. 390 Crores;

- Healthcare Services (HCS) PAT at Rs. 385 Crore; 37% YoY growth
- AHLL PAT loss of Rs. 4 Crores
- Apollo HealthCo PAT at Rs. 9 Crores

## **FY25 CONSOLIDATED RESULTS**

### **REVENUE**

**FY25 Revenues grew 14% YoY to Rs. 21,794 Crores;**

- Healthcare Services (HCS) Revenue at Rs. 11,147 Crores; 13% YoY growth
- AHLL Revenues at Rs. 1,554 Crores; 14% YoY growth
- Apollo HealthCo Revenues at Rs. 9,093 Crores; 16% YoY growth
- GMV of Apollo 24/7 at Rs. 3,007 Crores

### **EBITDA**

**FY25 Consolidated EBITDA grew 26% YoY to Rs. 3,022 Crores;**

- Healthcare Services (HCS) EBITDA at Rs. 2,701 Crores; 15% YoY growth
- AHLL EBITDA at Rs. 154 Crores; 32% YoY growth
- Apollo HealthCo EBITDA at Rs. 168 Crores

### **PAT**

**FY25 Consolidated PAT grew 61% YoY to Rs. 1,446 Crores;**

- Healthcare Services (HCS) PAT at Rs. 1,426 Crores; 25% YoY growth
- AHLL PAT loss of Rs. 27 Crores
- Apollo HealthCo PAT at Rs. 47 Crores

## Financial Performance – Q4FY25

### Consolidated Q4FY25 Performance

- Revenues at Rs. 55,923 mn vs Rs.49,439 mn in Q4 FY24; 13% YoY growth
- EBITDA grew by 20% at Rs. 7,699 mn vs Rs.6,405 mn in Q4 FY24. This is after Apollo 24/7 cost of Rs. 1,603 mn in the quarter (incl. Rs. 455 mn non-cash ESOP charge) vs Rs 1,508 mn in Q4 FY24.
- Reported PAT at Rs. 3,897 mn vs Rs.2,538 mn in Q4 FY24; 54% YoY growth
- Diluted EPS of Rs. 27.10 per share in Q4 FY25 (not annualized)

### Healthcare service Q4FY25 Performance

- Revenue at Rs. 28,220 mn vs Rs. 25,626 mn in Q4 FY24; 10% YoY growth
- EBITDA grew by 16% at Rs. 6,863 mn vs Rs. 5,931 mn in Q4 FY24; Margins at 24.3% in Q4 FY25
- PAT stood at Rs. 3,852 mn vs Rs. 2,803 mn in Q4 FY24, 37% YoY growth

### Apollo Health and Lifestyle Limited Q4FY25 Performance

- Revenue at Rs. 3,940 mn vs Rs. 3,547 mn in Q4 FY24; 11% YoY growth
- EBITDA grew by 32% at Rs. 472 mn vs Rs. 357 mn in Q4 FY24; Margins at 12.0% in Q4 FY25
- PAT loss of Rs. 43 mn vs loss of Rs. 87 mn in Q4 FY24

### Apollo HealthCo Q4FY25 Performance

- Revenue at Rs. 23,763 mn vs Rs. 20,267 mn in Q4 FY24; 17% YoY growth
- EBITDA at Rs. 363 mn vs Rs. 117 mn in Q4 FY24; Margins at 1.5 % in Q4 FY25
- PAT stood at Rs. 88 mn vs loss of Rs. 177 mn in Q4 FY24

## Financial Performance – FY25

### Consolidated FY25 Performance

- Revenues at Rs. 217,940 mn vs Rs. 190,592 mn in FY24; 14% YoY growth
- EBITDA grew by 26% at Rs. 30,219 mn vs Rs. 23,907 mn in FY24. This is after Apollo 24/7 cost of Rs. 5,857 mn in FY25 (incl. Rs. 1,076 mn non-cash ESOP charge) vs Rs. 7,077 mn in FY24.
- Reported PAT at Rs. 14,460 mn vs Rs.8,986 mn in FY24; 61% YoY growth
- Diluted EPS of Rs. 100.56 per share in FY25

### Healthcare service FY25 Performance

- Revenue at Rs. 111,475 mn vs Rs. 98,670 mn in FY24; 13% YoY growth
- EBITDA grew by 15% at Rs. 27,005 mn vs Rs. 23,558 mn in FY24; Margins at 24.2% in FY25
- PAT stood at Rs. 14,261 mn vs Rs. 11,450 mn in FY24, 25% YoY growth

### Apollo Health and Lifestyle Limited FY25 Performance

- Revenue at Rs. 15,535 mn vs Rs. 13,653 mn in FY24; 14% YoY growth
- EBITDA grew by 32% at Rs. 1,538 mn vs Rs. 1,166 mn in FY24; Margins at 9.9% in FY25
- PAT loss of Rs. 270 mn vs loss of Rs. 508 mn in FY24

### Apollo HealthCo FY25 Performance

- Revenue at Rs. 90,930 mn vs Rs. 78,269 mn in FY24; 16% YoY growth
- EBITDA at Rs. 1,676 mn vs loss of Rs. 817 mn in FY24; Margins at 1.8% in FY25
- PAT stood at Rs. 469 mn vs loss of Rs. 1,957 mn in FY24

## Q4FY25 Segment-wise Performance Update

### Healthcare Services (Hospitals)

As on March 31, 2025, Apollo Hospitals had 8,025 operating beds across the network (excluding AHLL & managed beds). The overall occupancy for hospitals was at 67% vs 65% in the same period in the previous year. IP volumes grew 4% in Q4 FY25 – and is the penultimate quarter which bears the base impact of Bangladesh patients, given the drop-off resulting from the change in Bangladesh government and pursuant change in visa application and norms.

Consolidated Revenues of the healthcare services division grew by 10% to Rs. 28,220 million in Q4 FY25 compared to Rs.25,626 million in Q4 FY24.

EBITDA (Post Ind AS 116) was at Rs. 6,863 million in Q4 FY25 compared to Rs. 5,931 million in Q4 FY24. EBITDA grew 16% YoY.

Revenues in the Tamil Nadu cluster grew by 7%, IP Volumes grew by 1%. ARPOB grew by 4% to Rs. 78,133. Overall occupancy in the cluster was 1337 beds (65% occupancy) as compared to 1,288 beds (63% occupancy) in the previous year.

In AP Telangana region, Revenues grew by 19%, IP volumes grew by 10%. ARPOB grew by 8% to Rs. 65,572. Occupancy in the cluster was 788 beds (64% occupancy) as compared to 712 beds (56% occupancy) in the previous year.

In Karnataka region, Revenues grew by 15%, IP volumes grew by 2%. ARPOB grew by 10% to Rs. 70,598. Occupancy in the cluster was 538 beds (70% occupancy) as compared to 512 beds (68% occupancy) in the previous year.

In Eastern region, Revenues grew by 8%, IP volumes grew by 4%. ARPOB grew by 7% to Rs. 48,462. Occupancy in the cluster was 1,367 beds (73% occupancy) as compared to 1,347 beds (74% occupancy) in the previous year.

In Western region, Revenues grew by 14%, IP volumes grew by 6%. ARPOB grew by 15% to Rs. 56,053. Occupancy in the cluster was 491 beds (56% occupancy) as compared to 492 beds (57% occupancy) in the previous year.

In Northern region, Revenues grew by 9%, IP volumes grew by 6%. ARPOB grew by 4% to Rs. 64,191. Occupancy in the cluster was 844 beds (70% occupancy) as compared to 801 beds (66% occupancy) in the previous year.

The strong performance in Karnataka and AP Telangana region, is testament of the Apollo brand resilience, and the consumers trust in Apollo as care-provider of choice in the regions. Apollo Hospitals' plans to increase penetration in Bangalore and Hyderabad through a mix of Brownfield and Greenfield projects.

Hyderabad: Apollo Hospitals has approved the brownfield expansion of 160 beds spread across the Jubilee Hills and Secunderabad facilities, which should become operational in the coming 3-4 years.

Bengaluru: Apollo Hospitals has acquired an existing 200-bed hospital in Sarjapur, which should come into the fold in the next 2 quarters augmenting the current care network and expanding the coverage in the city. This foray into Sarjapur would improve access for consumers in South-east Bengaluru, which is home to many technocrats and large IT businesses. Apollo Hospitals' has also acquired a 2.53 acre land in Sarjapur for a 500 bed Greenfield Hospital, which is expected to become operational in 3-4 years.

### **Apollo Health and Lifestyle Limited: Diagnostics and Retail Healthcare**

- AHLL Gross Revenue at Rs. 3,940 million; 11% YoY growth
- Diagnostics Revenue stood at Rs. 1,278 million and Spectra at Rs. 701 million

### **Apollo HealthCo: Digital Healthcare and Omni-channel Pharmacy platform**

- Offline Pharmacy distribution revenues at Rs. 20,844 million in Q4 FY25 while Revenues from Digital platform were at Rs. 2,919 million
- Overall Health Co Revenues were at Rs. 23,763 million representing 17% YoY growth.
- 266 net new stores were opened in this quarter, taking the total number to 6,626 stores.
- GMV of Apollo 24/7 at Rs. 7,954 million in Q4 FY25, growth of 11% over Q4 FY24.
- Avg Q4 FY25 run rate of 83K/day order across Pharma, Diagnostics Consultations (including IP/OP referrals) compared to 58K/day in Q4 FY24.

## CLINICAL EXCELLENCE HIGHLIGHTS

- Apollo Hospitals crossed the milestone of 25,000+ cumulative transplants, with Hyderabad playing a pivotal role—reaffirming Apollo’s leadership in complex, high-acuity care and transplant innovation.
- Apollo Children’s Hospital, Chennai successfully performed a left thoracoscopic upper lobectomy on a 9-month-old infant with congenital pulmonary airway malformation—demonstrating advanced pediatric surgical capabilities using minimally invasive techniques.
- Indraprastha Apollo Hospitals, Delhi performed a landmark double lung transplant on a 42-year-old male patient with end-stage interstitial lung disease, along with rare complex limb salvage surgeries and aggressive cancer reconstructions for international patients.
- Apollo Hospitals, Navi Mumbai conducted Maharashtra’s first Robotic Nipple-Sparing Mastectomy with TiLoop reconstruction on a BRCA-positive patient, and completed 78 bone marrow transplants while launching a new 12-bed Advanced Liver ICU.
- Apollo Cancer Institute, Teynampet performed a novel hemi-circumferential portal vein resection to treat advanced pancreatic cancer, preserving splenic vein drainage and avoiding secondary interventions.
- Apollo Hospitals, Hyderabad launched an innovative Joint Preservation Program and became the first in the network to complete 25 Fast-track Deep Brain Stimulation surgeries in a 24-day period, and pioneered the use of an atrial flow regulator implant in a pediatric pulmonary hypertension case.
- Apollo Hospitals, Bangalore performed a mitral valve edge-to-edge repair using the MitraClip, reinforcing its expertise in structural heart procedures.
- Apollo Hospitals, Madurai successfully treated a rare condition called hematohidrosis in a 20-year-old female patient.
- Apollo Hospitals, Mysore resected a rare acral fibromyxoma tumour from the palm of a 58-year-old male patient using a complex surgical procedure with full sensorimotor preservation.
- Apollo Hospitals, Kolkata carried out a robot-assisted choledochal cyst surgery for a two-year-old child, marking a milestone in pediatric robotic surgery in the region.

## NEW LAUNCHES, INITIATIVES AND PARTNERSHIPS

- Apollo Hospitals launched the Centre for Digital Health and Precision Medicine in collaboration with the University of Leicester, UK—focusing on AI-integrated diagnostics, genomics, and precision-led care transformation.
- A strategic Memorandum of Understanding (MoU) was signed with Mayapada Healthcare, Indonesia, to strengthen cross-border medical collaboration and clinical knowledge exchange across Southeast Asia.
- Apollo Hospitals, Navi Mumbai launched a dedicated 12-bed Advanced Liver ICU, supporting complex hepatology cases with state-of-the-art critical care infrastructure.
- Apollo Hospitals, Bangalore introduced 'Seniors First', a proactive geriatric care initiative that delivers personalized, preventive healthcare for India's ageing population.
- Apollo Hospitals, Hyderabad initiated a new Joint Preservation Program, offering early intervention through multidisciplinary, non-surgical therapies to delay or prevent joint replacements.
- Apollo Hospitals rolled out 'The Pink Book', a comprehensive institutional framework to safeguard healthcare workers and promote a robust culture of safety, trust, and accountability across the hospital network.

## AWARDS AND ACCOLADES

- Apollo Hospitals received 15 prestigious awards in Q4 FY25, reflecting its excellence in clinical care, green infrastructure, patient trust, and community engagement.
- Apollo Hospitals, Navi Mumbai emerged as a standout, receiving five major recognitions:
  - Big FM's Big Impact Creator Award (Super Speciality Hospitals, 2025)
  - Sakal Sanman Award
  - Best Super Speciality Hospital in Mumbai by the Navabharath Group
  - Leading Quaternary Care Hospital by the Times Group
  - IGBC Platinum Certification for excellence in green building standards, by the Indian Green Building Council
- Apollo Hospitals, Ahmedabad was honoured at the FICCI Medical Value Travel Awards for its role in attracting international patients and promoting India as a hub for high-quality, affordable care.

- In the Northeast, Apollo Hospitals, Guwahati was named Hospital of the Year by News18, and its affiliate Excelcare earned four recognitions:
  - Stroke Readiness (News18 Assam)
  - Best Practices in CSSD (CAHO)
  - Excellence in Infection Control (AHPI, Association of Hospital Providers (India))
  - Best Community Outreach Program (Ankuram)
  
- Apollo Hospitals, Hyderabad received two prestigious recognitions:
  - Certificate of Recognition from the Association of Healthcare Providers (India)
  - Stroke Center Certification from the American Heart Association
  
- Apollo Hospitals, Chennai was ranked among the World's Best Hospitals 2025 by Newsweek and named the Most Trusted Hospital by the Times Health Excellence Awards.
  
- Apollo Hospitals, Karnataka was honoured at the FICCI Women's Achievers Awards, recognising the institution's commitment to diversity, inclusion, and clinical excellence.

## About Apollo

*Apollo revolutionized healthcare when Dr. Prathap Reddy opened the first hospital in Chennai in 1983. Today, Apollo is the world's largest integrated healthcare platform with over 10,000 beds across 73 hospitals, 6,600+ pharmacies, 260+ clinics, 2,200+ diagnostic centres, and 800+ telemedicine centres. It is one of the world's leading cardiac centers, having performed over 3,00,000 angioplasties and 2,00,000 surgeries. Apollo continues to invest in research and innovation to bring the most cutting-edge technologies, equipment, and treatment protocols to ensure patients have access to the best care in the world. Apollo's 1,20,000 family members are dedicated to delivering exceptional care and leaving the world better than we found it.*

For further details, log onto: [www.apollohospitals.com](http://www.apollohospitals.com)

For further information, please contact:

For Media / Investors

R Krishnakumar  
Apollo Hospitals Ltd.  
[Krishnakumar\\_r@apollohospitals.com](mailto:Krishnakumar_r@apollohospitals.com)  
+91 44 2829 7840

Mayank Vaswani  
CDR India  
[mayank@cdr-india.com](mailto:mayank@cdr-india.com)  
+91 22 6645 1230

## Disclaimer

*Some of the statements in this document that are not historical facts are forward looking statements. These forward looking statements include our financial and growth projections as well as statements concerning our plans, strategies, intentions and beliefs concerning our business and the markets in which we operate.*

*These statements are based on information currently available to us, and we assume no obligation to update these statements as circumstances change. There are risks and uncertainties that could cause actual events to differ materially from these forward-looking statements. These risks include, but are not limited to, the level of market demand for our services, the highly-competitive market for the types of services that we offer, market conditions that could cause our customers to reduce their spending for our services, our ability to create, acquire and build new businesses and to grow our existing businesses, our ability to attract and retain qualified personnel, currency fluctuations and market conditions in India and elsewhere around the world, and other risks not specifically mentioned herein but those that are common to industry.*

*Further, this document may make references to reports and publications available in the public domain. Apollo Hospitals Enterprise Ltd. makes no representation as to their accuracy or that the company subscribes to those views / findings.*